Senesco Logo
Home About Us News and Media Our Technologies Clinical Development Commercialization Investor Relations Contact Us
   
  Senesco is a cancer therapeutics company employing its strong proprietary platform in eukaryotic translation initiation Factor 5A (eIF5A) technology to regulate cell death and survival. The Company's lead therapeutic candidate SNS01-T incorporates recent developments in siRNA, DNA regulation and nanotechnology. Senesco is building its portfolio with other potential eiF5A applications in cancer, inflammation and ischemia.
  Clinical Trials  
  Senesco is sponsoring a Phase 1b/2a clinical trial of SNS01-T for patients with multiple myeloma who have relapsed from, or failed to respond to, at least two previous treatment regimens. For contact information, please visit the study page on clinicaltrials.gov.

 
  youtube Latest Videos  
  10-25-13 Dave Getty Interviews Les Browne
 
  10-23-13 Presentation/Q&A at RedChip  
 
2014-3-12
Senesco Opens Two New Clinical Trial Sites and Initiates Treatment of the First Patient in South Africa
 
2014-3-10
Senesco Pays Off Line of Credit
 
2014-3-4
In Non-clinical Cancer Studies Senesco’s Therapeutic Candidate, SNS01-T, Works Synergistically in Combination with the Active Components of Revlimid® and Velcade® Studies Provide Additional Confirmation That SNS01-T Preferentially Targets Cancer Cells
 
  Disclaimer
facebook twitter youtube google+ linkedin